Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines

著者: Frederika A. van Nimwegen, Georgios Ntentas, Sarah C. Darby, Michael Schaapveld, Michael Hauptmann, Pieternella J. Lugtenburg, Cécile P.M. Janus, Laurien Daniëls, Flora E. van Leeuwen, David J. Cutter, Berthe M.P. Aleman - Blood 2017 被引用: 235

= .09). Twenty-five-year cumulative risks of HF following MLVDs of 0-15 Gy, 16-20 Gy, and ≥21 Gy were 4.4%, 6.2%, and 13.3%, respectively, in patients treated without anthracycline-containing chemotherapy, and 11.2%, 15.9%, and 32.9%, respectively, in patients treated with anthracyclines. We have derived quantitative estimates of HF risk in patients treated for HL following radiotherapy with or without anthracycline-containing chemotherapy. Our results enable estimation of HF risk for patients before treatment, during radiotherapy planning, and during follow-up.